Human FAS/APO-1 (CD95) Antibody from MYBIOSOURCE INC.
Search, find, compare suppliers for anti-Human FAS/APO-1 (CD95) antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | Human FAS/APO-1 (CD95) |
| Clone | [3.22] |
| Host Species | Mouse |
| Reactive Species | human |
| Isotype | IgG1 |
| Format | Protein A purified |
| Size | 100 tests |
| Concentration | n/a |
| Applications | Flow Cytometry (FC/FACS) |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | Activation of either the 55-kD tumor necrosis factor receptor (TNF-R1) or CD95 (Fas/Apo-1) causes apoptosis of cells and liver failure in mice, and has been associated with human liver disorders. The aim of this study was first to clarify the association between CD95 activation, hepatocyte apoptosis, and fulminant liver failure. Next, we investigated whether TNF-R1 and CD95 operate independently of each other in the induction of hepatocyte apoptosis. |
| Immunogen | n/a |
| Other Names | [hfas -FITC; human fas/Apo1 FITC CD95], [FAS; FAS; APT1; CD95; FAS1; APO-1; FASTM; ALPS1A; TNFRSF6; APT1; FAS1; TNFRSF6] |
| Gene, Accession # | [FAS/APO-1], Gene ID: 355, NCBI: NP_000034.1, UniProt: P25445 |
| Catalog # | MBS397692 |
| Price | $255 |
| Order / More Info | Human FAS/APO-1 (CD95) Antibody from MYBIOSOURCE INC. |
| Product Specific References | 1) The 55-kD tumor necrosis factor receptor and CD95 independently signal murine hepatocyte apoptosis and subsequent liver failure. Author : Leist M; Gantner F; K ?unstle G; Bohlinger I; Tiegs G; Bluethmann H; Wendel A Source : Mol Med, 2(1):109-24 1996 Jan 2) Regulation of CD95 ligand expression: a key element in immune regulation? Author : Brunner T; Yoo NJ; Griffith TS; Ferguson TA; Green DR Source : Behring Inst Mitt, (97):161-74 1996 Oct 3)Expression of CD95 antigen and Bcl-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease [published erratum appears in Am J Pathol 1996 Jul;149(1):346] Author : Nguyen PL; Harris NL; Ritz J; Robertson MJ Source : Am J Pathol, 148(3):847-53 1996 Mar 4) Relation of oxidative stress and glutathione synthesis to CD95(Fas/APO-1)-mediated apoptosis of adult T cell leukemia cells. Author : Kohno T; Yamada Y; Hata T; Mori H; Yamamura M; Tomonaga M; Urata Y; Goto S; Kondo T Source : J Immunol, 156(12):4722-8 1996 Jun 15 5) Clonal deletion of major histocompatibility complex class I-restricted CD4 CD8 thymocytes in vitro is independent of the CD95 (APO-1/Fas) ligand. Author : M ?uller KP; Mariani SM; Matiba B; Kyewski B; Krammer PH Source : Eur J Immunol, 25(10):2996-9 1995 Oct 6) Activation of the CD95 system increases with disease progression in human immunodeficiency virus type 1-infected children and adolescents. Author : B ?ohler T; B ?aumler C; Herr I; Groll A; Kurz M; Debatin KM Source : Pediatr Infect Dis J, 16(8):754-9 1997 Aug 7) Fc gammaRIII-mediated regulation of hematopoiesis in murine bone marrow cells by interleukin-3 and CD95 (Fas/Apo-1). Author : Yoshikawa H; Sakihama T; Nakajima Y; Tasaka K Source : Blood, 90(5):1911-9 1997 Sep 1 8) Human autoreactive and foreign antigen-specific T cells resist apoptosis induced by soluble recombinant CD95 ligand. Author : Zipp F; Martin R; Lichtenfels R; Roth W; Dichgans J; Krammer PH; Weller M Source : J Immunol, 159(5):2108-15 1997 Sep 1 9) The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Author : Fulda S; Sieverts H; Friesen C; Herr I; Debatin KM Research Center, Heidelberg. Source : Cancer Res, 57(17):3823-9 1997 Sep 1 10) Differential CD95 expression and function in T and B lineage acute lymphoblastic leukemia cells. Author : Karawajew L; Wuchter C; Ruppert V; Drexler H; Gruss HJ; D ?orken B; Ludwig W. D. Source : Leukemia, 11(8):1245-52 1997 Aug |
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166
sales@mybiosource.com
http://www.MyBioSource.com
Profile of MYBIOSOURCE INC.
Return to Antibodies